Recursion Pharmaceuticals: A Step Forward Towards Improving C. Difficile Treatment

Recursion Pharmaceuticals Product REC-163964
Recursion Pharmaceuticals Inc (RXRX) announced the initiation of an investigational new drug (IND)-enabling studies for REC-163964, a first-in-class, small molecule toxin inhibitor for possible prevention of recurrent Clostridium difficile (C. difficile) infections and potential prophylactic use in high-risk patients.

REC-163964 is a new chemical entity and the first to be . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.